Targeted Drug Delivery

Targeted Drug Delivery Novel approaches in targeted drug delivery for both small molecule and biopharmaceutical drugs Targeted Drug Delivery explores a new frontier in drug research that has become a focus for developing novel medications. The work discusses a wide range of approaches for targeting small molecules as well as peptide and macromolecular drugs, from prodrugs to drug conjugates to drug carriers and devices, helping readers to stay up to date on the latest developments in the field. The following key topics are addressed:

• Antibody conjugates, prodrugs, and suicide gene therapeutics
• Protac technology for selectively degrading target proteins
• Delivery of nucleic acid drugs
• Novel drug carriers, such as liposomes, vesicles, and nanoparticles
• Unmet medical needs for which there is a large market potential, such as viral infections and cancer For chemists, pharmacologists, and professionals in the wider pharmaceutical industry, Targeted Drug Delivery is a comprehensive guide on how to solve the greatest challenge in treating many diseases: delivering a pharmaceutically active substance to the target tissue in the body.

*Yogeshwar Bachhav is a pharmacist by training and holds a PhD in drug delivery systems from ICT, Mumbai (India). He has worked as research scientist for several years on a collaborative project between Pantec Biosolutions and Geneva University (Switzerland), and as formulation manager at Debiopharm Group, Lausanne (Switzerland). For the last 9 years he has been associated with AiCuris Anti-infective Cures AG (Germany) as in-charge for Pharmaceutical development of new drugs. In total, he has around 16 years of experience in the preformulation and formulation development of small molecules and peptides for oral, dermal and parenteral application and in drug substance manufacturing.*

Auteur
Yogeshwar Bachhav is a pharmacist by training and holds a PhD in drug delivery systems from ICT, Mumbai (India). He has worked as research scientist for several years on a collaborative project between Pantec Biosolutions and Geneva University (Switzerland), and as formulation manager at Debiopharm Group, Lausanne (Switzerland). For the last 5 years he has been working as Associate Director at AiCuris Anti-infective Cures GmbH, Germany and has been responsible for pharmaceutical development. In total, he has around 14 years of experience in the preformulation and formulation development of small molecules and/or peptides for oral, dermal and parenteral application. He has more than 16 international publications, 6 European patents and over 30 conference proceedings to his credit. He has recently edited a book for Wiley-VCH: Innovative Dosage Forms: Design and Development at Early Stage.